Co-Founder and Scientific Advisory Board Member
Dr. Emmanuelle Charpentier
Dr. Emmanuelle Charpentier co-founded CRISPR Therapeutics together with Rodger Novak and Shaun Foy. She is the Acting and Founding Director of the Max Planck Unit for the Science of Pathogens and a Director at the Max Planck Institute for Infection Biology, both in Berlin, Germany. Prior to joining Max Planck, Emmanuelle was awarded an Alexander von Humboldt professorship at the Helmholtz Centre for Infection Research in Braunschweig, where she headed the Department of Regulation in Infection Biology, and was a Professor at the Hannover Medical School. For many years, she also oversaw a research group at the Laboratory for Molecular Infection Medicine Sweden at Umeå University in Sweden. Emmanuelle studied microbiology and biochemistry at the University Pierre and Marie Curie in Paris, France, where she received her Ph.D. in Microbiology for her research at the Pasteur Institute.
Emmanuelle’s seminal research unveiled the key mechanisms of the CRISPR/Cas9 technology, laying the foundation for the use of CRISPR/Cas9 as a versatile and precise gene-editing tool. Numerous awards have recognized her work, including the Breakthrough Prize in Life Sciences, the Gruber Foundation International Prize in Genetics, the Kavli Prize in Nanoscience, the Japan Prize, the Leibniz Prize, the BBVA Foundation Frontiers of Knowledge Award, the Carus-Medal of the German National Academy of Science Leopoldina and the L'Oréal-UNESCO for Women in Science Award, among many others. TIME also recognized Emmanuelle as one of The Most Influential People in 2015.